Depressive Disorders - North America

Revenue in the Depressive Disorders market is projected to reach US$7.89bn in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 0.76%, resulting in a market volume of US$8.20bn by 2029.
In global comparison, most revenue will be generated United States (US$6.26bn in 2024).
In relation to total population figures, per person revenues of US$292.10 are generated in 2024.

Depressive disorders are a common type of mental illness. Symptoms include depressive moods such as feeling sad, low concentration, low self-worth, loss of interest in activities, and, in some cases, thoughts of suicide. Common treatments for depressive disorders include psychological treatments such as psychotherapy, behavioral therapy, and antidepressant medication.

The Depressive Disorders market in the Mental Health market represents the market for antidepressant drug sales. Different types of antidepressants are usually prescribed for the treatment of mild to serious cases of depression, e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitor (SNRIs), serotonin modulators, as well as tricyclic and tetracyclic antidepressants.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Novartis AG, Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, Patheon Inc, and Sandoz Inc.

Antidepressant drugs
Selective serotonin reuptake inhibitors (SSRIs)
Serotonin norepinephrine reuptake inhibitor (SNRIs)
Serotonin modulators
Tricyclic and tetracyclic antidepressants

Psychotherapy
Mood stabilizers
Anti-anxiety and stimulant medications
Behavioral therapy

The Depressive Disorders market in North America is experiencing significant growth due to several key factors. Customer preferences for effective and accessible treatment options, along with the increasing awareness and understanding of mental health issues, are driving the demand for Depressive Disorders medications and therapies. Additionally, local special circumstances, such as the high prevalence of mental health disorders and the availability of advanced healthcare infrastructure, contribute to the market's development. Customer preferences in North America are shifting towards more personalized and comprehensive treatment approaches for Depressive Disorders. Patients are seeking medications that not only alleviate symptoms but also address the underlying causes of their condition. This has led to an increased demand for antidepressant medications that target specific neurotransmitters in the brain, as well as psychotherapy options that provide patients with coping mechanisms and support. Additionally, there is a growing interest in alternative therapies, such as mindfulness and meditation, which can complement traditional treatment methods. The market is also influenced by the increasing awareness and understanding of mental health issues in North America. Efforts to reduce the stigma surrounding mental health have resulted in more individuals seeking help for Depressive Disorders. This has led to a larger patient pool and an increased demand for treatment options. Additionally, advancements in technology and the widespread use of the internet have made it easier for individuals to access information and resources related to mental health. This has further contributed to the growth of the market, as people are more informed and proactive about seeking treatment for Depressive Disorders. In North America, there are several local special circumstances that contribute to the development of the Depressive Disorders market. The region has a high prevalence of mental health disorders, with a significant portion of the population experiencing symptoms of depression. This creates a large market potential for pharmaceutical companies and healthcare providers. Additionally, North America has well-established healthcare infrastructure, including a network of hospitals, clinics, and mental health centers. This infrastructure supports the timely diagnosis and treatment of Depressive Disorders, further driving the market's growth. Underlying macroeconomic factors also play a role in the development of the Depressive Disorders market in North America. The region has a high GDP per capita, which allows individuals to afford the cost of medications and therapies. Additionally, the presence of private health insurance coverage and government healthcare programs ensures that a significant portion of the population has access to affordable treatment options. These factors contribute to the market's growth by increasing the affordability and accessibility of Depressive Disorders treatments in North America. Overall, the Depressive Disorders market in North America is experiencing growth due to customer preferences for personalized and comprehensive treatment options, increasing awareness and understanding of mental health issues, local special circumstances such as high prevalence and advanced healthcare infrastructure, and underlying macroeconomic factors that support affordability and accessibility of treatments.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.